Presentations The CBL-B Inhibitor, NX-0255, Improves Human Drug Enhanced Tumor Infiltrating Lymphocyte (DeTIL-0255) Expansion and T-cell Function in Full-scale Runs
Presentations Universal Expansion of CBL-B–inhibited Tumor-Infiltrating Lymphocytes, DeTIL-0255, from Women with Ovarian Cancer: Process Validation
Presentations A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies
Presentations Initial Clinical Characterization of Novel Proximal Biomarkers for NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies
Presentations A Novel Small Molecule Inhibitor of CBL-B Shows Potent Antitumor Activity in Combination with Pmel-1 Adoptive Cell Transfer in an Aggressive Mouse Melanoma Model
Presentations NX-1607, a Small Molecule Inhibitor of the CBL-B E3 Ubiquitin Ligase, Promotes T and NK Cell Activation and Enhances NK-mediated ADCC in a Mouse Lymphoma Tumor Model
'